Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CV Sciences (CVSI) EBIT (2016 - 2025)

CV Sciences' EBIT history spans 14 years, with the latest figure at -$275000.0 for Q3 2025.

  • For Q3 2025, EBIT rose 19.35% year-over-year to -$275000.0; the TTM value through Sep 2025 reached $644000.0, up 126.47%, while the annual FY2024 figure was -$505000.0, 115.03% down from the prior year.
  • EBIT for Q3 2025 was -$275000.0 at CV Sciences, down from -$131000.0 in the prior quarter.
  • Across five years, EBIT topped out at $5.8 million in Q1 2023 and bottomed at -$8.8 million in Q4 2021.
  • The 5-year median for EBIT is -$889000.0 (2023), against an average of -$1.2 million.
  • The largest annual shift saw EBIT surged 480.33% in 2023 before it plummeted 110.76% in 2024.
  • A 5-year view of EBIT shows it stood at -$8.8 million in 2021, then soared by 75.97% to -$2.1 million in 2022, then surged by 58.16% to -$889000.0 in 2023, then skyrocketed by 216.87% to $1.0 million in 2024, then crashed by 126.47% to -$275000.0 in 2025.
  • Per Business Quant, the three most recent readings for CVSI's EBIT are -$275000.0 (Q3 2025), -$131000.0 (Q2 2025), and $11000.0 (Q1 2025).